“…The strong bias seen for insulin aspart is not due to access, with identical open access to all options in both countries, or supported by the available literature, which suggests comparable pharmacokinetic/pharmacodynamic properties across the three available rapid‐acting analogues . In contrast, the dominance of glargine is unsurprising, being the only readily available truly once‐daily basal insulin option due to its smooth long‐acting plasma concentration profile for many years now, in addition to the purported potential benefits in hypoglycaemia, irrespective of timing of injection . It is also possible that choice of insulin reflects some form of pharmaceutical bias or simply the historical order that new analogues became available locally, with clinicians persisting with established insulin choices.…”